1. 「喘息予防・管理ガイドライン2018」作成委員. 喘息予防・管理ガイドライン 2018. ⼀般社団法⼈⽇本アレルギー学会喘息ガイドライン専⾨部会 (監修), 協和企画, 東京, 2018.
2. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204.
3. Fukutomi Y, Nakamura H, Kobayashi F, et al. Nationwide cross-sectional population-based study on the prevalences of asthma and asthma symptoms among Japanese adults. Int Arch Allergy Immunol 2010;153:280–287.
4. Chastek B, Korrer S, Nagar SP, et al. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. J Manag Care Spec Pharm 2016;22:848–861.
5. Nakazawa T, Dobashi K. Current asthma deaths among adults in Japan. Allergology International 2004;53:205–209.
6. Ekici A, Ekici M, Kara T, et al. Negative mood and quality of life in patients with asthma. Qual Life Res 2006;15:49–56.
7. Uchmanowicz B, Panaszek B, Uchmanowicz I, et al. Clinical factors affecting quality of life of patients with asthma. Patient Prefer Adherence 2016;10:579–11.
8. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015;46:1308–1321.
9. Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: A systematic literature review. Clin Ther 2017;39:2216–2229.
10. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144:1016–1025.
11. Serra-Batlles J, Plaza V, Morejón E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322–1326.
12. Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116–124.
13. Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J 2010;17: 4–80.
14. Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967;2:951–953.
15. Bennich HH, Ishizaka K, Johansson SG, et al. Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968;38:151–152.
16. Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2018;18:454–466.
17. Wang YH, Angkasekwinai P, Lu N, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007;204:1837–1847 .
18. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell– mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673–680.
19. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–490.
20. Sayama K, Diehn M, Matsuda K, et al. Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunol 2002;3:5.
21. Pène J, Rousset F, Brière F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci USA 1988;85:6880–6884.
22. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;4:15–24.
23. Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 2010;17:e85–93.
24. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004;10:1095–1103.
25. Kabata H, Moro K, Fukunaga K, et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun 2013;4:2675.
26. Huang Y, Guo L, Qiu J, et al. IL-25-responsive, lineage-negative KLRG1hi cells are multipotential “inflammatory” type 2 innate lymphoid cells. Nat Immunol 2014;16:161–169.
27. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033–1039.
28. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537–548.
29. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403–409.
30. Ricciardolo FLM, Sorbello V, Folino A, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol 2017;140:395–406.
31. Weller PF, Rand TH, Goelz SE, et al. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:7430–7433.
32. Nakajima H. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 1994;179:1145– 1154.
33. Nobs SP, Kayhan M, Kopf M. GM-CSF intrinsically controls eosinophil accumulation in the setting of allergic airway inflammation. J Allergy Clin Immunol 2019;143:1513–1524.
34. Teran LM, Noso N, Carroll M, et al. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol 1996;157:1806–1812.
35. Alam R, Stafford S, Forsythe P, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442–3448.
36. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449–456.
37. Lopez AF, Sanderson CJ, Gamble JR, et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219–224.
38. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by adipose tissue- associated c-Kit+Sca-1+ lymphoid cells. Nature 2010;463:540–544.
39. Cohn L, Homer RJ, Marinov A, et al. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997;186:1737–1747.
40. Barker RL, Gleich GJ, Pease LR. Acidic precursor revealed in human eosinophil granule major basic protein cDNA. J Exp Med 1988;168:1493–1498.
41. Gleich GJ, Loegering DA, Bell MP, et al. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 1986;83:3146–3150.
42. Ten RM, Pease LR, McKean DJ, et al. Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med 1989;169:1757–1769.
43. Ueki S, Melo RCN, Ghiran I, et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 2013;121:2074–2083.
44. Neves JS, Perez SAC, Spencer LA, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci USA 2008;105:18478–18483.
45. Brottman GM, Regelmann WE, Slungaard A, et al. Effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatr Pulmonol 1996;21:159–166.
46. Gleich GJ, Frigas E, Loegering DA, et al. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979;123:2925–2927.
47. Hernnäs J, Särnstrand B, Lindroth P, et al. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 1992;59:352–363.
48. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388–395.
49. Ishizaka T, Ishizaka K, Tomioka H. Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. J Immunol 1972;108:513–520.
50. Metcalfe D, Boyce JA. Mast cell biology in evolution. J Allergy Clin Immunol 2006;117:1227–1229.
51. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010;10:440–452.
52. Ishizaka T, Ishizaka K, Orange RP, et al. The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J Immunol 1970;104:335–343.
53. Keown MB, Henry AJ, Ghirlando R, et al. Participation of the N-terminal region of Cepsilon3 in the binding of human IgE to its high-affinity receptor FcεRI. Biochemistry 1998;37:8863–8869.
54. Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem 1981;256:11939–11943.
55. Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982;129:1627–1631.
56. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol 2000;67:841–846.
57. Dvorak AM, Costa JJ, Morgan ES, et al. Diamine oxidase-gold ultrastructural localization of histamine in human skin biopsies containing mast cells stimulated to degranulate in vivo by exposure to recombinant human stem cell factor. Blood 1997;90:2893–2900.
58. Brown JK, Tyler CL, Jones CA, et al. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:227–236.
59. Tsai M, Galli SJ. IgE and mast cells in allergic disease. Nat Med 2012;18:693–704.
60. Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989;339:150–152.
61. Plaut M, Pierce JH, Watson CJ, et al. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 1989;339:64–67.
62. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135–142.
63. Wang S-W, Oh CK, Cho SH, et al. Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts. J Allergy Clin Immunol 2005;115:287–294.
64. Okumura S, Sagara H, Fukuda T, et al. FcεRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J Allergy Clin Immunol 2005;115:272–279.
65. Asakura T, Ishii Y, Chibana K, et al. Leukotriene D4 stimulates collagen production from myofibroblasts transformed by TGF-β. J Allergy Clin Immunol 2004;114:310–315.
66. Yu M. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006;116:1633–1641.
67. Koshino T, Teshima S, Fukushima N, et al. Identification of basophils by immunohistochemistry in the airways of post-mortem cases of fatal asthma. Clin Exp Allergy 1993;23:919–925.
68. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879–885.
69. Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699–1705.
70. Sawant KV, Poluri KM, Dutta AK, et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci Rep 2016;6:33123.
71. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045–1049.
72. Fujisawa T, Kato Y, Atsuta J, et al. Chemokine production by the BEAS-2B human bronchial epithelial cells: Differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines. J Allergy Clin Immunol 2000;105:126–133.
73. Inoue H, Massion PP, Ueki IF, et al. Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils. Am J Respir Cell Mol Biol 1994;11:651–663.
74. Massion PP, Hébert CA, Leong S, et al. Staphylococcus aureus stimulates neutrophil recruitment by stimulating interleukin-8 production in dog trachea. Am J Physiol 1995;268:L85–94.
75. Honda K, Wada H, Nakamura M, et al. IL-17A synergistically stimulates TNF-α-induced IL- 8 production in human airway epithelial cells: A potential role in amplifying airway inflammation. Exp Lung Res 2016;42:205–216.
76. Ong CWM, Elkington PT, Brilha S, et al. Neutrophil-derived MMP-8 drives AMPK- dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog 2015;11:e1004917–21.
77. Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 1998;4:615–618.
78. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002;416:291–297.
79. Afonso PV, Janka-Junttila M, Lee YJ, et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell 2012;22:1079–1091.
80. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741–744.
81. Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001;276:35494–35499.
82. Kikuchi I, Kikuchi S, Kobayashi T, et al. Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Respir Cell Mol Biol 2006;34:760–765.
83. Wang S-Z, Wraith A, Bowden JJ, et al. Neutrophils induce damage to respiratory epithelial cells infected with respiratory syncytial virus. Eur Respir J 1998;12:612–618.
84. Toussaint M, Jackson DJ, Swieboda D, et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med 2017;23:681–691.
85. Polak D, Hafner C, Briza P, et al. A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions. J Allergy Clin Immunol 2019;143:1143–1152.
86. Strickland I, Kisich K, Hauk PJ, et al. High constitutive glucocorticoid receptor β in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 2001;193:585–593.
87. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014;133:1557– 1563.
88. Ordoñez CL, Shaughnessy TE, Matthay MA, et al. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am J Respir Crit Care Med 2000;161:1185–1190.
89. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.
90. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol 2019;144:1–12.
91. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218–224.
92. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315–323.
93. Opina MT, Moore WC. Phenotype-driven therapeutics in severe asthma. Curr Allergy Asthma Rep 2017;17:10.
94. Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137:1347–1358.
95. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225–1229.
96. Wark PA, Johnston SL, Moric I, et al. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002;19:68–75
97. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982–986.
98. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749–1759.
99. Wark PAB, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937– 947.
100. Baraldo S, Contoli M, Bazzan E, et al. Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma. J Allergy Clin Immunol 2012;130:1307–1314.
101. Pauwels RA, Busse WW, O'Byrne PM, et al. The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. Control Clin Trials 2001;22:405–419.
102. Bateman ED, Buhl R, O'Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. J Allergy Clin Immunol 2015;135:1457–1464.
103. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19–24.
104. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367–376.
105. Jayaram L. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483–494.
106. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985;318:635–641.
107. Bamberger CM, Bamberger AM, de Castro M, et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435–2441.
108. Scherrer LC, Dalman FC, Massa E, et al. Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex. J Biol Chem 1990;265:21397–21400.
109. Oakley RH, Jewell CM, Yudt MR, et al. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. J Biol Chem 1999;274:27857–27866.
110. Martinez-Balbás MA, Bannister AJ, Martin K, et al. The acetyltransferase activity of CBP stimulates transcription. EMBO J 1998;17:2886–2893.
111. Kurihara I, Shibata H, Suzuki T, et al. Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Mol Cell Endocrinol 2002;189:181–189.
112. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891–6903.
113. Richards DF, Fernandez M, Caulfield J, et al. Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production. Eur J Immunol 2000;30:2344–2354.
114. Royer B, Varadaradjalou S, Saas P, et al. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001;31:694–704.
115. Arock M, Zuany-Amorim C, Singer M, et al. Interleukin-10 inhibits cytokine generation from mast cells. Eur J Immunol 1996;26:166–170.
116. Takanaski S, Nonaka R, Xing Z, et al. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 1994;180:711–715.
117. Buelens C, Verhasselt V, De Groote D, et al. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol 1997;27:756–762.
118. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
119. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551–556.
120. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994;93:33–39.
121. Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995;181:33–40.
122. Goleva E, Li L-B, Eves PT, et al. Increased glucocorticoid receptor β alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006;173:607–616.
123. Li L-B, Leung DYM, Martin RJ, et al. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor β in steroid-resistant asthma. Am J Respir Crit Care Med 2010;182:877–883.
124. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134–141.
125. Hawrylowicz C, Richards D, Loke T-K, et al. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol 2002;109:369–370.
126. Vazquez-Tello A, Semlali A, Chakir J, et al. Induction of glucocorticoid receptor-β expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin Exp Allergy 2010;40:1312–1322.
127. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;181:4089–4097.
128. Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009;41:342–347.
129. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010;363:1211–1221.
130. Hirota T, Takahashi A, Kubo M, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet 2011;43:893–896.
131. Demenais F, Margaritte-Jeannin P, Barnes KC, et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat Genet 2018;50:42–53.
132. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173–1183.
133. Koster ES, Maitland-van der Zee AH, Tavendale R, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 2011;66:1546–1552.
134. Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004;101:18099– 18104.
135. Mohamed NA, Abdel-Rehim ASM, Farres MN, et al. Influence of glucocorticoid receptor gene NR3C1 646 C>G polymorphism on glucocorticoid resistance in asthmatics: a preliminary study. Cent Eur J Immunol 2015;3:325–330.
136. Naylor B. The shedding of the mucosa of the bronchial tree in asthma. Thorax 1962;17:69– 72.
137. Aikawa T, Shimura S, Sasaki H, et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992;101:916–921.
138. James AL, Maxwell PS, Pearce-Pinto G, et al. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166:1590–1595.
139. Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999;104:1001– 1006.
140. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405–410.
141. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997;156:229–233.
142. James AL, Paré PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989;139:242–246.
143. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 2018;128:997–1009.
144. Le Cras TD, Acciani TH, Mushaben EM, et al. Epithelial EGF receptor signaling mediates airway hyperreactivity and remodeling in a mouse model of chronic asthma. Am J Physiol Lung Cell Mol Physiol 2011;300:L414–421.
145. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029–1036.
146. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107:14170–14175.
147. Song DJ, Cho JY, Lee SY, et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009;183:5333–5341.
148. Chen G, Korfhagen TR, Xu Y, et al. SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest 2009;119:2914–2924.
149. Enomoto Y, Orihara K, Takamasu T, et al. Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack. J Allergy Clin Immunol 2009;124:913–920.
150. Abraham I, Alhossan A, Lee CS, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 2016;71:593–610.
151. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
152. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376:2448–2458.
153. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid- dependent severe asthma. N Engl J Med 2018;378:2475–2485.
154. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017;377:936–946.
155. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294–1302.
156. Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J 2017;50:1700670.
157. Pease JE, Horuk R. Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opin Drug Discov 2014;9:467–483.
158. O'Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo- controlled trial. Lancet Respir Med 2016;4:797–806.
159. Danek CJ, Lombard CM, Dungworth DL, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol 2004;97:1946–1953.
160. Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J Allergy Clin Immunol 2017;139:1176–1185.
161. Haj Salem I, Gras D, Joubert P, et al. Persistent reduction of mucin production after bronchial thermoplasty in severe asthma. Am J Respir Crit Care Med 2019;199:536–538.
162. Chupp G, Laviolette M, Cohn L, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J 2017;50:1700017.
163. Sha Q, Truong-Tran AQ, Plitt JR, et al. Activation of airway epithelial cells by Toll-Like receptor agonists. Am J Respir Cell Mol Biol 2004;31:358–364.
164. Adam E, Hansen KK, Astudillo Fernandez O, et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J Biol Chem 2006;281:6910– 6923.
165. Dahlin K, Mager EM, Allen L, et al. Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 2004;31:309–316.
166. Visintin A, Latz E, Monks BG, et al. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 2003;278:48313–48320.
167. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll- like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042–1049.
168. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll- like receptor 4 triggering of airway structural cells. Nat Med 2009;15:410–416.
169. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010;107:11942–11947.
170. Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278:1612–1615.
171. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115–122.
172. Guillot L, Medjane S, Le-Barillec K, et al. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways. J Biol Chem 2004;279:2712–2718.
173. Ramadas RA, Ewart SL, Medoff BD, et al. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 2011;44:134–145.
174. Chustz RT, Nagarkar DR, Poposki JA, et al. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2011;45:145– 153.
175. Angkasekwinai P, Park H, Wang Y-H, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007;204:1509–1517.
176. Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007;204:253–258.
177. Willart MA, Deswarte K, Pouliot P, et al. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012;209:1505–1517.
178. Chua KY, Stewart GA, Thomas WR, et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 1988;167:175–182.
179. Pichavant M, Charbonnier A-S, Taront S, et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J Allergy Clin Immunol 2005;115:771–778.
180. Li B, Zou Z, Meng F, et al. Dust mite-derived Der f 3 activates a pro-inflammatory program in airway epithelial cells via PAR-1 and PAR-2. Mol Immunol 2019;109:1–11.
181. Kouzaki H, O’Grady SM, Lawrence CB, et al. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol 2009;183:1427–1434.
182. Tomee JF, van Weissenbruch R, de Monchy JG, et al. Interactions between inhalant allergen extracts and airway epithelial cells: effect on cytokine production and cell detachment. J Allergy Clin Immunol 1998;102:75–85.
183. Zhou Q, Ho AWS, Schlitzer A, et al. GM-CSF-licensed CD11b+ lung dendritic cells orchestrate Th2 immunity to Blomia tropicalis. J Immunol 2014;193:496–509.
184. Llop-Guevara A, Chu DK, Walker TD, et al. A GM-CSF/IL-33 pathway facilitates allergic airway responses to sub-threshold house dust mite exposure. PLoS One 2014;9:e88714.
185. Park CS, Choi YS, Ki SY, et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J 1998;12:872–878.
186. Schröder JM, Kameyoshi Y, Christophers E. RANTES, a novel eosinophil-chemotactic cytokine. Ann N Y Acad Sci 1994;725:91–103.
187. Becker S, Reed W, Henderson FW, et al. RSV infection of human airway epithelial cells causes production of the beta-chemokine RANTES. Am J Physiol 1997;272:L512–520.
188. Farquhar MG, Palade GE. Junctional complexes in various epithelia. J Cell Biol 1963;17:375–412.
189. Georas SN, Rezaee F. Epithelial barrier function: At the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol 2014;134:509–520.
190. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123:1777–1788.
191. Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998;141:1539–1550.
192. Martìn-Padura I, Lostaglio S, Schneemann M, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998;142:117–127.
193. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320–1323.
194. Walters RW, Freimuth P, Moninger TO, et al. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 2002;110:789–799.
195. Fanning AS, Jameson BJ, Jesaitis LA, et al. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998;273:29745–29753.
196. LaFemina MJ, Rokkam D, Chandrasena A, et al. Keratinocyte growth factor enhances barrier function without altering claudin expression in primary alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010;299:L724–734.
197. LaFemina MJ, Sutherland KM, Bentley T, et al. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice. Am J Respir Cell Mol Biol 2014;51:550–558.
198. Herbert CA, King CM, Ring PC, et al. Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. Am J Respir Cell Mol Biol 1995;12:369– 378.
199. Nakamura T, Hirasawa Y, Takai T, et al. Reduction of skin barrier function by proteolytic activity of a recombinant house dust mite major allergen Der f 1. J Invest Dermatol 2006;126:2719–2723.
200. Gumbiner B, Stevenson B, Grimaldi A. The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J Cell Biol 1988;107:1575–1587.
201. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science 1991;254:1359–1361.
202. Srinivasan B, Kolli AR, Esch MB, et al. TEER measurement techniques for in vitro barrier model systems. J Lab Autom 2015;20:107–126.
203. Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011;128:549–556.
204. Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997;10:2376–2379.
205. Zepp JA, Morrisey EE. Cellular crosstalk in the development and regeneration of the respiratory system. Nat Rev Mol Cell Biol 2019;20:551–566.
206. Ordoñez CL, Khashayar R, Wong HH, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001;163:517–523.
207. Koeppen M, McNamee EN, Brodsky KS, et al. Detrimental role of the airway mucin Muc5ac during ventilator-induced lung injury. Mucosal Immunol 2012;6:762–775.
208. Ehre C, Worthington EN, Liesman RM, et al. Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proc Natl Acad Sci USA 2012;109:16528–16533.
209. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2013;505:412–416.
210. Lusuardi M, Capelli A, Di Stefano A, et al. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J 2001;18:571–588.
211. Klockars M, Reitamo S. Tissue distribution of lysozyme in man. J Histochem Cytochem 1975;23:932–940.
212. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553–560.
213. Singh PK, Jia HP, Wiles K, et al. Production of β-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998;95:14961–14966.
214. Schroeder BO, Wu Z, Nuding S, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 2011;469:419–423.
215. Bowes D, Clark AE, Corrin B. Ultrastructural localisation of lactoferrin and glycoprotein in human bronchial glands. Thorax 1981;36:108–115.
216. Drago-Serrano ME, la Garza-Amaya de M, Luna JS, et al. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol 2012;12:1–9.
217. Kruzel ML, Bacsi A, Choudhury B, et al. Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology 2006;119:159–166.
218. Stolk J, Seersholm N, Kalsheker N. Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis 2006;1:151–160.
219. Lee CH, Igarashi Y, Hohman RJ, et al. Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am Rev Respir Dis 1993;147:710–716.
220. Kouzaki H, Matsumoto K, Kikuoka H, et al. Endogenous Protease inhibitors in airway epithelial cells contribute to eosinophilic chronic rhinosinusitis. Am J Respir Crit Care Med 2017;195:737–747.
221. Cayrol C, Duval A, Schmitt P, et al. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. Nat Immunol 2018;19:375–385.
222. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011;186:4375–4387.
223. Raundhal M, Morse C, Khare A, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest 2015;125:3037–3050.
224. Prasad D, Rothlin CV, Burrola P, et al. TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 2006;33:96–108.
225. Scutera S, Fraone T, Musso T, et al. Survival and migration of human dendritic cells are regulated by an IFN-α-inducible Axl/Gas6 pathway. J Immunol 2009;183:3004–3013.
226. Schmid ET, Pang IK, Carrera Silva EA, et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. Elife 2016;5:e12414.
227. Zahuczky G, Kristóf E, Majai G, et al. Differentiation and glucocorticoid regulated apopto- phagocytic gene expression patterns in human macrophages. Role of Mertk in enhanced phagocytosis. Role of Mertk in enhanced phagocytosis. PLoS One 2011;6:e21349.
228. Fujimori T, Grabiec AM, Kaur M, et al. The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol 2015;8:1021–1030.
229. Lu Q, Gore M, Zhang Q, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999;398:723–728.
230. Stitt TN, Conn G, Gore M, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995;80:661–670.
231. Mark MR, Chen J, Hammonds RG, et al. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 1996;271:9785–9789.
232. Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022–30027.
233. Lew ED, Oh J, Burrola PG, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife 2014;3:e03385.
234. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207–2216.
235. Huang M, Rigby AC, Morelli X, et al. Structural basis of membrane binding by Gla domains of vitamin K–dependent proteins. Nat Struct Mol Biol 2003;10:751–756.
236. Bandyopadhyay PK. Vitamin K-dependent γ-glutamylcarboxylation: an ancient posttranslational modification. Vitam Horm 2008;78:157–184.
237. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–225.
238. Taylor IC, Roy S, Varmus HE. Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. Oncogene 1995;11:2619–2626.
239. Sasaki T, Knyazev PG, Cheburkin Y, et al. Crystal structure of a C-terminal fragment of growth srrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. J Biol Chem 2002;277:44164–44170.
240. Weinger JG, Gohari P, Yan Y, et al. In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation. J Neurochem 2008;106:134–146.
241. Weinger JG, Brosnan CF, Loudig O, et al. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J Neuroinflammation 2011;8:49–18.
242. Rothlin CV, Ghosh S, Zuniga EI, et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007;131:1124–1136.
243. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100–103.
244. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251–306.
245. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890–898.
246. Bosurgi L, Cao YG, Cabeza-Cabrerizo M, et al. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science 2017;356:1072–1076.
247. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001;293:306–311.
248. Scott RS, McMahon EJ, Pop SM, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411:207–211.
249. Zagórska A, Través PG, Lew ED, et al. Diversification of TAM receptor tyrosine kinase function. Nat Immunol 2014;15:920–928.
250. Wallet MA, Sen P, Flores RR, et al. MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med 2008;205:219–232.
251. Schell SL, Soni C, Fasnacht MJ, et al. Mer receptor tyrosine kinase signaling prevents self- ligand sensing and aberrant selection in germinal centers. J Immunol 2017;199:4001–4015.
252. Woolley KL, Gibson PG, Carty K, et al. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154:237–243.
253. Grabiec AM, Denny N, Doherty JA, et al. Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma. J Allergy Clin Immunol 2017;140:1144–1146.
254. Chan PY, Carrera Silva EA, De Kouchkovsky D, et al. The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity. Science 2016;352:99–103.
255. Fujino N, Brand OJ, Morgan DJ, et al. Sensing of apoptotic cells through Axl causes lung basal cell proliferation in inflammatory diseases. J Exp Med 2019;216:2184–2201.
256. Modena BD, Tedrow JR, Milosevic J, et al. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med 2014;190:1363–1372.
257. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–373.
258. Richter A, Puddicombe SM, Lordan JL, et al. The contribution of interleukin (IL)-4 and IL- 13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001;25:385–391.
259. Global Initiative for Asthma. Global strategy for asthma management and prevention. Fontana, WI, USA, 2019. Available at: https://www.ginasthma.org/.
260. Hickman DL, Johnson SW. Evaluation of the aesthetics of physical methods of euthanasia of anesthetized rats. J Am Assoc Lab Anim Sci 2011;50:695–701.
261. Reddel RR, Ke Y, Gerwin BI, et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1988;48:1904–1909.
262. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31:e154.
263. Lefever S, Vandesompele J, Speleman F, et al. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 2009;37:D942–945.
264. Spandidos A, Wang X, Wang H, et al. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 2009;38:D792–799.
265. Spandidos A, Wang X, Wang H, et al. A comprehensive collection of experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript abundance. BMC Genomics 2008;9:633.
266. Bauer JA, Thompson TA, Church DR, et al. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24-dihydroxyvitamin D2. Prostate 2003;55:159–167.
267. Harada M, Hirota T, Jodo AI, et al. Functional analysis of the thymic stromal lymphopoietin variants in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2009;40:368–374.
268. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001;25:402–408.
269. Ishii T, Niikura Y, Kurata K, et al. Time-dependent distinct roles of Toll-like receptor 4 in a house dust mite-induced asthma mouse model. Scand J Immunol 2018;38:42–49.
270. Misharin AV, Morales-Nebreda L, Mutlu GM, et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol 2013;49:503–510.
271. Schreck R, Baeuerle PA. NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol 1990;10:1281–1286.
272. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997;158:3483–3491.
273. Kimura H, Inukai Y, Takii T, et al. Molecular analysis of constitutive IL-1α gene expression in human melanoma cells: autocrine stimulation through NF-kappaB activation by endogenous IL-1α. Cytokine 1998;10:872–879.
274. Hutti JE, Turk BE, Asara JM, et al. IkappaB kinase β phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 2007;27:7451– 7461.
275. Schuijs MJ, Willart MA, Vergote K, et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science 2015;349:1106–1110.
276. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. Immunity 2019;50:975– 991.
277. Juncadella IJ, Kadl A, Sharma AK, et al. Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 2013;493:547–551.
278. Wertz IE, Newton K, Seshasayee D, et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2015;528:370–375.
279. McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993;150:5436–5444.
280. McKenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993;90:3735–3739.
281. Morita H, Kubo T, Rückert B, et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J Allergy Clin Immunol 2019;143:2190– 2201.
282. Fujino N, Kubo H, Maciewicz RA. Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype. Lab Invest 2017;97:1047–1062.
283. Shibata T, Habiel DM, Coelho AL, et al. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. J Immunol 2014;192:3569–3581.
284. Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010;29:5254– 5264.
285. Ekman C, Stenhoff J, Dahlbäck B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 2010;8:838–844.
286. Haque SJ, Harbor P, Tabrizi M, et al. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 1998;273:33893– 33896.
287. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000;19:2577–2584.
288. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258–2261.
289. Shinkai A, Yoshisue H, Koike M, et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999;163:1602–1610.
290. Her E, Frazer J, Austen KF, et al. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991;88:1982–1987.
291. Simon HU, Yousefi S, Dibbert B, et al. Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27:3536–3539.
292. Saha S, Doe C, Mistry V, et al. Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax 2009;64:671–676.
293. Fitzpatrick AM, Higgins M, Holguin F, et al. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol 2010;125:851–857.
294. Goruppi S, Ruaro E, Varnum B,et al. Requirement of phosphatidylinositol 3-kinase- dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 1997;17:4442–4453.
295. Taggart CC, Greene CM, McElvaney NG, et al. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002;277:33648–33653.
296. Kurowska-Stolarska M, Alivernini S, Melchor EG, et al. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nat Commun 2017;8:15877.
297. Fritz HK, Gustafsson A, Ljungberg B, et al. The Axl-regulating tumor suppressor miR-34a is increased in ccRCC but does not correlate with Axl mRNA or Axl protein levels. PLoS One 2015;10:e0135991.
論文の公開元へ
